The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged "activated" state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.本發明係關於嵌合抗原受體(CAR)。CARs能夠利用配體結合域性質再導免疫細胞對選定標靶之特異性及反應性。特別地，本發明係關於其中胞外配體結合為衍生自CD19單株抗體(較佳4G7)之scFV的嵌合抗原受體。本發明亦關於編碼該CAR之多核苷酸、載體及在表面表現該CAR之分離細胞。本發明亦關於改造免疫細胞使其表面表現4G7-CAR而賦予轉導細胞延長「活化」狀態之方法。本發明尤其適用於治療B-細胞淋巴瘤及白血病。
